Back

ACACIA-HCM: Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy

28 August 2026 (11:45 - 11:58)
Organised by: Logo
Congress Presentation Part of: HOT LINE 1 Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ahmad Masri

Oregon Health & Science University Medical Group, Portland (United States of America)

14 More presentations in this session

Presentation thumbnail
CARDIO-TTRansform: efficacy and safety of eplontersen in patients with transthyretin amyloid cardiomyopathy
Doctor M. Maurer (New York, US)
Slides Video
Presentation thumbnail
Discussant review - CARDIO-TTRansform
Professor G. Sinagra (Trieste, IT)
Slides Video
Presentation thumbnail
Panel discussion - CARDIO-TTRansform
Presentation thumbnail
SINGLE-AF: Anticoagulation for atrial fibrillation with intermediate stroke risk
Professor B. Joung (Seoul, KR)
Slides Video
Presentation thumbnail
Discussant review - SINGLE-AF
Professor I. Van Gelder (Groningen, NL)
Slides Video

Access the full session

Session thumbnail
HOT LINE 1
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 11:45 CET
You may be interested in
thumbnail
Congress Presentation
Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A pre-specified analysis of MAPLE-HCM
31 August 2025
thumbnail
Congress Session
Ask the Trialists - ACACIA-HCM
28 August 2026
thumbnail
Congress Presentation
ODYSSEY-HCM: Mavacamten in nHCM
30 August 2025
thumbnail
Congress Presentation
Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial
13 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources